Adma Biologics (ADMA) Raw Materials (2016 - 2025)

Adma Biologics has reported Raw Materials for 10 years, with the latest figure at $96.6 million in Q4 2025.

• For the quarter ending Q4 2025, Raw Materials rose 59.76% year-over-year to $96.6 million; the trailing twelve-month figure through Dec 2025 stood at $96.6 million (up 59.76% YoY), and the FY2025 full-year result was $96.6 million, up 59.76% from the prior year.
• Raw Materials for Q4 2025 stood at $96.6 million, up from $87.8 million in the prior quarter.
• The five-year high for Raw Materials was $100.4 million in Q2 2025, with the low at $33.1 million in Q2 2021.
• Historically, Raw Materials has averaged $57.4 million across 5 years, with a median of $53.0 million in 2023.
• Annual changes were most pronounced in 2023 — Raw Materials grew 4.35% — and 2025, when it jumped 76.14%.
• Adma Biologics' Raw Materials stood at $36.8 million in 2021, then jumped by 32.34% to $48.6 million in 2022, then climbed by 8.95% to $53.0 million in 2023, then grew by 14.1% to $60.5 million in 2024, then surged by 59.76% to $96.6 million in 2025.
• The last three Raw Materials figures came in at $96.6 million (Q4 2025), $87.8 million (Q3 2025), and $100.4 million (Q2 2025), per Business Quant data.